Harvard Heart Letter

Research we're watching: No heart risk-or benefit-from diabetes drug Onglyza

In the largest and most comprehensive study of the heart effects of a diabetes drug, the blood sugar-lowering drug saxagliptin (Onglyza) showed no benefit in protecting against heart disease or stroke. Importantly, the drug also did not increase cardiovas

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In